TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04795830

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Bioceramic root repair material as pulp dressing in pulpotomy in primary molars
Description: BC RRM-F, a novel premixed bioceramic-based putty, can be used as a pulp dressing to promote pulp healing and repair with an added convenience for the pediatric patient. The aim of the present study is to evaluate the efficacy of a bioceramic root repair material as pulp dressing in pulpotomy in primary molars. The success of this material as pulpotomy dressing in primary molars will be evaluated clinically and radiographically in comparison to mineral trioxide aggregate pulpotomy. Both materials will be compared in terms of ease of handling, time to perform procedure and convenience of application. Each material's success will be evaluated by comparing its performance with or without the added peripheral seal of a stainless steel crown.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Bioceramic root repair material as pulp dressing in pulpotomy in primary molars
Description: BC RRM-F, a novel premixed bioceramic-based putty, can be used as a pulp dressing to promote pulp healing and repair with an added convenience for the pediatric patient. The aim of the present study is to evaluate the efficacy of a bioceramic root repair material as pulp dressing in pulpotomy in primary molars. The success of this material as pulpotomy dressing in primary molars will be evaluated clinically and radiographically in comparison to mineral trioxide aggregate pulpotomy. Both materials will be compared in terms of ease of handling, time to perform procedure and convenience of application. Each material's success will be evaluated by comparing its performance with or without the added peripheral seal of a stainless steel crown.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Mineral Trioxide Aggregate as pulp dressing in primary molars (MTA)
Description: MTA's sealing ability, biocompatibility, ability to stimulate hard tissue formation and its regenerative ability when used in contact with pulp tissues has made MTA pulpotomy the new gold standard as opposed to formocresol pulpotomy in treating the amputated pulp stumps of primary molars.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Mineral Trioxide Aggregate as pulp dressing in primary molars (MTA)
Description: MTA's sealing ability, biocompatibility, ability to stimulate hard tissue formation and its regenerative ability when used in contact with pulp tissues has made MTA pulpotomy the new gold standard as opposed to formocresol pulpotomy in treating the amputated pulp stumps of primary molars.
Study: NCT05080439

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diacutaneous Fibrolysis
Description: Application of diacutaneous fibrolysis in teres major

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: Dry needling based on fast-in fast-out technique in the teresa major muscle
Study: NCT06056011

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Connex CSVM with Timmy3 module
Description: Connex Vital Signs Monitor with the Timmy3 Investigational module

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Connex CSVM with Timmy3 module
Description: Connex Vital Signs Monitor with the Timmy3 Investigational module

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Connex CSVM with Timmy3 module
Description: Connex Vital Signs Monitor with the Timmy3 Investigational module
Study: NCT06366984

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: plastibell
Description: plastibell used for circumcision

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: open method
Description: open method used for circumcision
Study: NCT06520306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine combined with methylene blue for iliac fascia block
Description: Ultrasound-guided fascia iliaca block using different concentrations of methylene blue combined with ropivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine combined with methylene blue for iliac fascia block
Description: Ultrasound-guided fascia iliaca block using different concentrations of methylene blue combined with ropivacaine
Study: NCT03631290

Intervention type: BEHAVIORAL
Intervention: Deprescribing Intervention
Description: The deprescribing program was implemented as a clinical quality improvement project for patients receiving dialysis. Patients taking specific potentially inappropriate medications (PIMs) were identified in the medical record. The PIMs of interest included gabapentinoids, clonidine, alpha blockers, muscle relaxants, and Z-drugs. If their nephrologist agreed to attempt deprescribing the PIM, either the nephrologist (Provider Only Communication) or a study team member (pharmacist or nurse, Provider/Patient Communication) would engage the patient in discussion about deprescribing. This discussion included patient education materials about the risk of the medication. If the patient agreed, they were provided taper instructions (if indicated) and were followed up at 1 month and 3 months.~The patient was also invited to enroll in a study to be interviewed about the deprescribing decision and experience, and undergo brief assessment of geriatric problems at baseline and at 3 months.
Study: NCT05182385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: All patients with hematological relapse will additionally receive Blinatumomab immunotherapy (first cycle: 9 ug/d c.i.v. on d1 until d7 and 28 ug/d c.iv. on d8 until d28; second cycle: 28 ug/d c.iv. on d1 to d28) in six-week cycles (4 weeks on Blinatumomab, 2 weeks off Blinatumomab).~All patients with molecular relapse will additionally receive Blinatumomab immunotherapy at 28 ug/d c.iv. on d1 until d28 in six-week cycles (4 weeks on Blinatumomab, 2 weeks off Blinatumomab.)~Patients eligible for a second cycle shall not receive Blinatumomab starting dose independent from relapse type.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: All patients with hematological relapse will additionally receive Blinatumomab immunotherapy (first cycle: 9 ug/d c.i.v. on d1 until d7 and 28 ug/d c.iv. on d8 until d28; second cycle: 28 ug/d c.iv. on d1 to d28) in six-week cycles (4 weeks on Blinatumomab, 2 weeks off Blinatumomab).~All patients with molecular relapse will additionally receive Blinatumomab immunotherapy at 28 ug/d c.iv. on d1 until d28 in six-week cycles (4 weeks on Blinatumomab, 2 weeks off Blinatumomab.)~Patients eligible for a second cycle shall not receive Blinatumomab starting dose independent from relapse type.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: In phase I of the study all eligible patients will receive increasing doses of Venetoclax on days -7 to -1 (Venetoclax dose-titration) in the first cycle and continuous dosing of Venetoclax at a pre-specified target dose (TD, p.o., once daily, d1 to d42) in six-week cycles for a maximum of two cycles.~In phase II of the study all eligible patients will receive the recommended phase 2 dose (RP2D) of Venetoclax in six-week cycles for a maximum of two cycles. RP2D will be MTD.~Patients eligible for a second cycle shall not receive Venetoclax dose-titration independent from relapse type.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: In phase I of the study all eligible patients will receive increasing doses of Venetoclax on days -7 to -1 (Venetoclax dose-titration) in the first cycle and continuous dosing of Venetoclax at a pre-specified target dose (TD, p.o., once daily, d1 to d42) in six-week cycles for a maximum of two cycles.~In phase II of the study all eligible patients will receive the recommended phase 2 dose (RP2D) of Venetoclax in six-week cycles for a maximum of two cycles. RP2D will be MTD.~Patients eligible for a second cycle shall not receive Venetoclax dose-titration independent from relapse type.
Study: NCT04944563

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Segmentectomy
Description: Patients receive segmentectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lobectomy
Description: Patients receive lobectomy
Study: NCT05674149

Intervention type: DEVICE
Group type: OTHER
Intervention: camera
Description: photographs using multi-spectral camera
Study: NCT06506838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: For patients with the soft tissue sarcoma, the standard doxorubicin monotherapy regimen involves administering 37.5 mg/m² intravenously on days 1-2 of every 3 week . The treatment includes 3 cycles of neoadjuvant chemotherapy before surgery and 3 cycles of adjuvant chemotherapy after surgery, totaling 6 cycles. Anlotinib is administered at 12mg/d QD，day1\~14, 21d/cycle. Neoadjuvant radiotherapy is conducted before surgery, starting after the second chemotherapy cycle, using stereotactic body radiation therapy (SBRT) with a dose of 4\*10 Gy. Radical resection surgery is performed after the third chemotherapy cycle.
Study: NCT06258863

Intervention type: PROCEDURE
Intervention: incision type
Description: Total mastectomy was performed using one of the four incision types

Intervention type: PROCEDURE
Intervention: incision type
Description: Total mastectomy was performed using one of the four incision types

Intervention type: PROCEDURE
Intervention: incision type
Description: Total mastectomy was performed using one of the four incision types

Intervention type: PROCEDURE
Intervention: incision type
Description: Total mastectomy was performed using one of the four incision types
Study: NCT06067308

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Performance of CTPA
Description: Exposure to CT scan and injection of IV contrast
Study: NCT04586296

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: IVR will consist of a 3 minute call at a decreasing interval from the time of surgery. Questions will assess pain control, signs of infection, prosthesis failure.
Study: NCT05102331

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lavender Oil Aromatherapy
Description: Participants will be given a dental bib to wear. Three drops of the lavender oil will be placed on the fabric of the bib and the participant will be instructed to relax for 20 minutes.~The lavender oil is produced by doTERRA and has Gas Chromatography Mass Spectrometry analysis showing 35.66% linalool without any contaminants

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oil
Description: Participants will be given a dental bib to wear. Three drops of the placebo oil will be placed on the fabric of the bib and the participant will be instructed to relax for 20 minutes.~Refined jojoba oil which has no color or smell

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BMAB procedure
Description: SOC BMAB procedure. The procedure takes approximately 20 minutes to complete and is performed on the posterior superior iliac crest of the pelvic bone. Between 5 and 10 mL of 1% lidocaine will be injected into the site of the BMAB 5 minutes prior to the procedure beginning. No systemic premedications will be allowed including opioids or benzodiazepines. If during the procedure, participants continue to report severe anxiety or pain, the practitioner may consider providing 1mg of lorazepam or morphine as a rescue medication. The aspirate needle and core biopsy needle will be the standard needle provided by the BMAB kit

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: BMAB procedure
Description: SOC BMAB procedure. The procedure takes approximately 20 minutes to complete and is performed on the posterior superior iliac crest of the pelvic bone. Between 5 and 10 mL of 1% lidocaine will be injected into the site of the BMAB 5 minutes prior to the procedure beginning. No systemic premedications will be allowed including opioids or benzodiazepines. If during the procedure, participants continue to report severe anxiety or pain, the practitioner may consider providing 1mg of lorazepam or morphine as a rescue medication. The aspirate needle and core biopsy needle will be the standard needle provided by the BMAB kit
Study: NCT05666661

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sound and light therapy (BBT and FL group)
Description: During intervention, the participants close their eyes and wear an eye mask and stereo earphones. They then listen to 30 minutes of 10 Hz BBT music (intercalated with relaxing music) through their mobile phone. The intervention music was first embedded in the participant's mobile phone and the BBT music application was purchased from the mobile phone app (Brainwave Studio software, Dalcoms Inc). When listening to music, 10 Hz light stimulation was added to the BBT and FL group (using a mobile phone). Table 1 shows the intervention status. The rhythmical photic stimulation program was a commercially available mobile phone app (Strobe Therapy software released by FuwhatSoft).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sound therapy group (BBT)
Description: Participants in the sound therapy group (BBT) listened to 30 minutes of 10 Hz BBT music (intercalated with relaxing music) through their mobile phones. Except for rhythmical photic stimulation, the other steps were the same as the BBT and FL group.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Relaxing music group
Description: Participants listened to 30 minutes of relaxing music (the same as that of the experimental groups) through their mobile phone. Except for rhythmical photic stimulation and 10 Hz BBT, the other steps were the same as the experimental groups.
Study: NCT03853304

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: + Folic acid
Description: Salt fortified with folic acid

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: + Folic acid
Description: Salt fortified with folic acid

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: + Vitamin B12
Description: Salt fortified with vitamin B12

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: + Vitamin B12
Description: Salt fortified with vitamin B12

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DFS
Description: Salt fortified with iron and iodine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DFS
Description: Salt fortified with iron and iodine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DFS
Description: Salt fortified with iron and iodine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DFS
Description: Salt fortified with iron and iodine
Study: NCT06456138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib will be administrated orally every day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib will be administrated orally from day 1 to day 14 per 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab will be administered at full dose (200mg, Q3W) on the patient who received the efficacy evaluation of stable disease (SD) or partial response (PR) or complete response (CR) after 2 cycles' treatment of trametinib plus anlotinib.
Study: NCT05401591

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein shake
Description: Participant will drink a protein shake made using each of the four protein types.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Protein shake
Description: Participant will drink a protein shake made using each of the four protein types.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein shake
Description: Participant will drink a protein shake made using each of the four protein types.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein shake
Description: Participant will drink a protein shake made using each of the four protein types.
Study: NCT05200884

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine 2%
Description: The child will be injected with lidocaine 2% and After 10 minutes the treatment will be completed , Pain during injection and treatment will be assessed using the FLACC scale and pain after injection and treatment will be evaluated using the Wong-Baker FACES pain rating scale

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Articaine 4%
Description: The child will be injected with 4% Articaine and After 10 minutes the treatment will be completed , Pain during injection and treatment will be assessed using the FLACC scale and face scale
Study: NCT04796025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab; Bevacizumab Biosimilar
Description: 1-4 cycles, intra-arterial infusion: sindilimab 200mg + bevacizumab 7.5mg/kg, q3w; 5-18 cycles: Sintilimab (200mg ivdrip D1 Q3W)+Bevacizumab Biosimilar (15mg/kg ivdrip D1 Q3W）
Study: NCT04085042

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PIVC pack
Description: The PIVC pack is a sterile container that includes inside all the need devices to perform peripheral catheterization. The pack is color-coded to inform healthcare professionals about the catheter caliber inside.
Study: NCT05822648

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project Health
Description: Project Health will be delivered in six 1-hour group sessions that will be held weekly. In addition, participants will be asked to complete 30 mins of response inhibition and attention trainings once per week between the sessions. This program promotes to retain the gradual lifestyle modification designed to bring energy intake into balance with energy output and the food response inhibition and attention training, but will adapt the dissonance-induction activities to focus on the negative effects of developing T2D in addition to the negative effects of obesity, overeating, and a sedentary lifestyle.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Video Control
Description: We selected a T2D management psychoeducational comparison condition. To match Project Health, the educational videos will be delivered in 6 1-hour blocks. The educational group will be instructed to watch videos on nutrition, exercise, and how to maintain general health during the lifespan
Study: NCT04340960

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Monitoring
Description: Patients in this group will receive home monitoring for NIBP (non-invasive blood pressure), SPO2 (pulse oximetry), and pain scores. These will be monitored 4 times a day for 2 weeks following surgery.
Study: NCT05369364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Zanubrutinib 80mg qd po, 6 consecutive weeks
Study: NCT06090448

Intervention type: DEVICE
Group type: OTHER
Intervention: EarSwitch device
Description: The Earswitch™ device consists of an earpiece made from silicon or similar bio-compatible material and incorporates a miniature camera. The earpiece sits within the ear canal and is not in direct contact with the eardrum and the camera is not in contact with the ear-canal. The camera detects voluntary movement from the tensor tympani muscle as presented at the eardrum and the Earswitch system translates this movement to an external virtual keypad or similar to allow the patient to communicate nonverbally.

Intervention type: DEVICE
Group type: OTHER
Intervention: EarSwitch device
Description: The Earswitch™ device consists of an earpiece made from silicon or similar bio-compatible material and incorporates a miniature camera. The earpiece sits within the ear canal and is not in direct contact with the eardrum and the camera is not in contact with the ear-canal. The camera detects voluntary movement from the tensor tympani muscle as presented at the eardrum and the Earswitch system translates this movement to an external virtual keypad or similar to allow the patient to communicate nonverbally.
Study: NCT05369364

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone, iv, 40 mg/d, for 4 days (The 4-day course of dexamethasone was repeated in the case of lack of response by day 10)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone, iv, 40 mg/d, for 4 days (The 4-day course of dexamethasone was repeated in the case of lack of response by day 10)
Study: NCT06069830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4 cycles of ESA regimen with sandwiched radiotherapy
Description: Pegaspargase, 2500U/m2, i.m. d1; etoposide, 200mg, p.o., d2-d4; Dexamethasone, 40mg, p.o. d2-d4；

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 cycles of ESA regimen sequential radiotherapy and 2 cycles of PD-1 monoclonal antibody combined with pegaspargase
Description: Pegaspargase, 2500U/m2, IM, d1; PD-1 monoclonal antibody, 200mg, i.v. d2;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 cycles of ESA regimen, 2 cycles of PD-1 monoclonal antibody and concurrent radiotherapy, 2 cycles of PD-1 monoclonal antibody combined with pegaspargase
Description: PD-1 monoclonal antibody, 200mg, i.v. d1
Study: NCT04812535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IFX-1
Description: IFX-1 Monotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IFX-1 + pembrolizumab combination therapy
Description: IFX-1 + pembrolizumab combination therapy
Study: NCT05074823

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine 0.1 mg
Description: Patients will receive 3mL of bupivacaine (heavy) 0.5% in addition to 0.5 ml of a preservative-free ketamine 0.1 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine 0.2 mg
Description: will receive 3mL of bupivacaine (heavy) 0.5% in addition to 0.5 ml of a preservative-free ketamine 0.2 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine 0.3 mg
Description: will receive 3mL of bupivacaine (heavy) 0.5% in addition to 0.5 ml of a preservative-free ketamine 0.3 mg/kg
Study: NCT05865834

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A smartphone application
Description: app will have 2 modules: Chill zone and sleep; Chill zone has 9 sub-modules which are meditation, breathing techniques, family time, art time, funny sayings, reframe stress and relax, diet and cooking tips, mini courses and how to become better. The sub-modules of sleep are: wind down, sleep music, storytelling, nature sounds and beautiful nature. These modules will be approved by a clinical psychologist to help people with symptoms of depression and anxiety. Skills learned include emotion recognition, emotional management, behavioral activation (being active), recognizing and challenging unhelpful thoughts and cognitive restructuring to plan for their future.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pictorial educational leaflets
Description: the control group will receive self-reading educational leaflets, the majority of which are pictorial. These leaflets will be approved by a clinical psychologist to help people with symptoms of depression and anxiety.
Study: NCT04937842

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: microtransplantation, HLA-mismatched donor peripheral stem cell infusion
Description: infusion of granulocyte colony stimulating factor (G-CSF) mobilized HLA-mismatched peripheral blood stem cells (GPBSC)